Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Uric acid concentrations increase after fructose ingestion

08 Mar 2018

Intakes of fructose, regardless of source, elevate uric acid levels in the circulation, reports a study.

The investigators randomized 73 participants to one of three groups to ingest small (205 g) and large (410 g) servings of apple segments, small (170 mL) and large (340 mL) servings of apple juice, or a glucose and a fructose control beverage to determine whether fructose present in fruit is of sufficient quantity or in a form that will increase uric acid concentration.

Participants within each group ingested both treatments in a crossover design. There was 26.7 g fructose in the fructose control and the large servings of apple and juice. Test foods were ingested within 10 min. The investigators took blood samples at baseline and at 30 and 60 min after intake.

Plasma uric acid concentrations escalated following intakes of all fructose-containing treatments and dropped after the glucose beverage. At 30 minutes, the mean uric acid increase was 15 µmol/L (95 percent CI, 10–21 µmol/L) for the fructose control, and 19 µmol/L (8–30 µmol/L) and 17 µmol/L (9–24 µmol/L) for the large servings of apple and apple juice, respectively.

No difference was seen in change in uric acid between baseline and 30 minutes when comparing the apple (3 µmol/L; −8 to 14 µmol/L) and apple juice (−7 µmol/L; −18 to 5 µmol/L) with the fructose control.

Any form of treatment had no effect on blood pressure taken 70 min after ingestion (p>0.05). There was no difference in change in satiety scores between the fructose and glucose control beverages (p>0.05). Participants who ingested whole apple felt more satiated after 30 min compared with apple juice intake.

Furthermore, the amount of glucose in each treatment was reflected by the glycaemic response.

“Longer-term studies are required to assess how small and transient increases in plasma uric acid contribute to health,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.